Abstract
Inflammatory responses rapidly detect pathogen invasion and mount a regulated reaction. However, dysregulated anti-pathogen immune responses can provoke life-threatening inflammatory pathologies collectively known as cytokine release syndrome (CRS), exemplified by key clinical phenotypes unearthed during the SARS-Cov-2 pandemic. The underlying pathophysiology of CRS remains elusive. We found that FLIP, a protein that controls caspase-8 death pathways, was highly expressed in myeloid cells of COVID-19 lungs. FLIP controlled CRS by fueling a STAT3-dependent inflammatory program. Indeed, constitutive expression of a viral FLIP homologue in myeloid cells triggered a STAT3-linked, progressive and fatal inflammatory syndrome in mice, characterized by elevated cytokine output, lymphopenia, lung injury and multiple organ dysfunctions that mimicked human CRS. As STAT3-targeting approaches relieved inflammation, immune disorders, and organ failures in these mice, targeted intervention towards this pathway could suppress the lethal CRS inflammatory state.
One sentence summary FLIP-expressing myeloid cells are key drivers of CRS through aberrant overexpression of STAT3 pathway. STAT3-targeting is effective in mitigating CRS like severe COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04438629
Funding Statement
This work was jointly supported by both S. Ugel grants of the Fondazione Italian Association for Cancer Research (AIRC, MFAG project: 21509) and PRIN program of Italian Ministry of Education, University and Research (MIUR, CUP: B38D19000140006) and V. Bronte grants funded by Fondazione Cariverona (ENACT Project), Fondazione TIM (Immunovid Project), Fondazione AIRC (23788), Cancer Research Institute (Clinic and Laboratory Integration Program, CLIP 2020), European Research Commission (Euronanomed III, Joint Traslational Call_2017, Project RESOLVE) and MIUR (CUP: B38D19000260006).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review board of Azienda Ospedaliera Universitaria di Verona Prot. n.17963 (25 March 2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ScRNA-seq data generated in this study are deposited in the Gene Expression Omnibus (GEO) under the accession number GSE168098.
